General Updates

Aurobindo Pharma Limited announced the completion of a US FDA Pre-Approval Inspection (PAI) at its 100% stepdown subsidiary, Eugia Steriles Private Limited. The inspection, held from June 10 to June 19, 2026, at the facility in Andhra Pradesh, concluded with five observations. The company has stated it will respond to these observations within the stipulated timeframe. This update is significant for investors as a successful resolution of these observations is crucial for securing FDA approvals for new products manufactured at this facility, impacting the company's future revenue potential from the US market.